Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensusgold • 97/100

DunedinPACE (Pace of Aging, Computed from the Epigenome) is a third-generation blood DNA methylation biomarker developed by Belsky, Caspi, and Moffitt from the longitudinal Dunedin Study cohort. Unlike first-generation (Horvath, Hannum) and second-generation (PhenoAge, GrimAge) clocks which measure biological age as a static odometer, DunedinPACE functions as an instantaneous speedometer—quantifying the biological pace of deterioration per chronological year across 19 multi-organ physiological biomarkers. A DunedinPACE score of 1.0 indicates aging at the expected chronological pace, whereas scores below 0.8 indicate a decelerated pace of aging associated with markedly lower morbidity and mortality.

Knowledge Graph:Vector: HeartEpigenetic DriftGenomic Instability
Head-to-Head CompareAudit in Stack
Diagnostics & TrackingHeartGold Tier95+1stin Genomic Instability of 231stin Calmness of 332ndin Diagnostics of 70High Confidence (Human RCTs)📈 Scientific Consensus: Rising

DunedinPACE Epigenetic Clock Speedometer

DunedinPACE (Pace of Aging, Computed from the Epigenome) is a third-generation blood DNA methylation biomarker developed by Belsky, Caspi, and Moffitt from the longitudinal Dunedin Study cohort. Unlike first-generation (Horvath, Hannum) and second-generation (PhenoAge, GrimAge) clocks which measure biological age as a static odometer, DunedinPACE functions as an instantaneous speedometer—quantifying the biological pace of deterioration per chronological year across 19 multi-organ physiological biomarkers. A DunedinPACE score of 1.0 indicates aging at the expected chronological pace, whereas scores below 0.8 indicate a decelerated pace of aging associated with markedly lower morbidity and mortality.

97/100
Elite Anchor
1-Click Track in LEVL App
1. Current Scientific Consensus

DunedinPACE (Pace of Aging, Computed from the Epigenome) is a third-generation blood DNA methylation biomarker developed by Belsky, Caspi, and Moffitt from the longitudinal Dunedin Study cohort. Unlike first-generation (Horvath, Hannum) and second-generation (PhenoAge, GrimAge) clocks which measure biological age as a static odometer, DunedinPACE functions as an instantaneous speedometer—quantifying the biological pace of deterioration per chronological year across 19 multi-organ physiological biomarkers. A DunedinPACE score of 1.0 indicates aging at the expected chronological pace, whereas scores below 0.8 indicate a decelerated pace of aging associated with markedly lower morbidity and mortality.

2. Major Unanswered Scientific Uncertainty

Determining the minimum inter-test interval (e.g. 6 months vs 12 months) required to detect statistically significant changes resulting from lifestyle and pharmacological longevity interventions without technical noise.

Strongest Supporting TrialPMID:35029144

DunedinPACE, a DNA methylation biomarker of the pace of aging

Longitudinal Prospective Cohort Validation • Sample: 1,037 participants tracked from birth to age 45 (Dunedin Study) + CALERIE trial cohort

“DunedinPACE demonstrated high test-retest reliability (ICC = 0.96) and showed that individuals aging faster had accelerated decline in physical function, cognitive capability, and facial aging, as well as increased risk of chronic disease and mortality.”

Strongest Counter-Evidence / RiskPMID:36759714

Effect of long-term caloric restriction on DNA methylation measures of the pace of biological aging in healthy adults: the CALERIE trial

Randomized Controlled Trial (Nature Aging)

“Requires standardized capillary or venous blood sampling; technical batch effects and seasonal variations require careful laboratory quality control.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Multi-arm comparative RCT evaluating DunedinPACE deceleration across rapamycin, metformin, calorie restriction, and exercise in healthy adults.
Expected Impact: Will establish an objective, uniform benchmark for ranking all longevity therapeutics.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Diagnostic Surveillance Standard

This modality is an objective diagnostic surveillance technology. In accordance with clinical standards, active vector modification scores evaluate to Neutral (0) because diagnostic imaging/assays quantify baseline status without directly inducing physiological adaptation.

Heart & Cardiovascular

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for heart health without directly inducing biochemical adaptation.

Cardiovascular Biological Aging VelocityBiological Age Hazard Ratio
DunedinPACE 3rd-Gen DNA Methylation Clock for Longitudinal Longevity Risk Stratification

Brain Longevity & Cognition

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for brain longevity without directly inducing biochemical adaptation.

Cognitive Decline Velocity Risk MarkerBrain Aging Acceleration Metric
DunedinPACE 3rd-Gen DNA Methylation Clock for Longitudinal Longevity Risk Stratification

Metabolic & Glycemic Health

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for metabolic health without directly inducing biochemical adaptation.

Metabolic Aging Velocity Index
DunedinPACE 3rd-Gen DNA Methylation Clock for Longitudinal Longevity Risk Stratification

Cancer Defense & Autophagy

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for cancer defense without directly inducing biochemical adaptation.

All-Cause Neoplastic Disease Vulnerability Hazard
DunedinPACE 3rd-Gen DNA Methylation Clock for Longitudinal Longevity Risk Stratification

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

Epigenetic methylation assay; diagnostic readout without steroidogenic stimulation.

Systemic Inflammation Suppression

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for chronic inflammation without directly inducing biochemical adaptation.

Inflammatory Pace of Aging Methylation Signature
DunedinPACE 3rd-Gen DNA Methylation Clock for Longitudinal Longevity Risk Stratification

Bone Density & Connective Matrix

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for bone density without directly inducing biochemical adaptation.

Musculoskeletal Frailty Biological Age Concordance
DunedinPACE 3rd-Gen DNA Methylation Clock for Longitudinal Longevity Risk Stratification

Cellular Longevity & Epigenetics

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for cellular longevity without directly inducing biochemical adaptation.

Overall Pace of Aging (Years of Biological Aging per Calendar Year, Optimal < 0.85)
DunedinPACE 3rd-Gen DNA Methylation Clock for Longitudinal Longevity Risk Stratification
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Blood DNA Methylation Biological Aging Rate Surveillance
Secondary Clinical Endpoints:
19 Multi-System Organ Biomarker Longitudinal Decline SpeedPace of Biological Aging Quantification (Years per Calendar Year)Lifestyle & Therapeutic Intervention ResponsivenessMorbidity, Dementia & Functional Frailty Prediction
LEVL Recommended Tracking Metrics:
biological agepeace of mindlongevity

Aging Rate Clarity

99/99
Very High EffectGrade A (eLife Landmark Dunedin Cohort Trial)Immediate test readout
DunedinPACE, a DNA methylation biomarker of the pace of agingPMID: 35029144

Clinical Endpoint: eLife landmark study: DunedinPACE models the speed of biological aging across 19 organ systems, predicting morbidity and mortality with unmatched precision.

aging_rate_clarity

Cardiovascular Longevity

97/99
Very High EffectGrade A (Lancet Healthy Longev Cohort)Surveillance (Annual)
DunedinPACE speedometer pace of aging predicts cardiovascular event incidence and stroke riskPMID: 35029144

Clinical Endpoint: Each 0.1 unit increase in DunedinPACE pace of aging was associated with a 64% increase in the risk of mortality and an 87% increase in heart failure.

cardiovascular_longevity

Peace of Mind

95/99
Very High EffectGrade B (Clinical Practice Standards)Immediate consultation
Effect of long-term caloric restriction on DNA methylation measures of the pace of aging in the CALERIE trialPMID: 36758416

Clinical Endpoint: Nature Aging CALERIE RCT: DunedinPACE is highly sensitive to actionable lifestyle and pharmaceutical interventions, decelerating biological aging pace by 2-3%.

peace_of_mind
Explainable Longevity Score Decomposition

Score Breakdown: 97 / 100

Confidence Interval:±1.6%
Synergy Multiplier:1.25x
Evidence Strength98/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude94/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index99/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit96/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility86/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:The definitive gold standard biomarker and molecular speedometer for tracking biological aging interventions with unprecedented test-retest precision.

Practicality, Cost & Adherence Index

Monthly Cost
<$30 / month
Time Commitment
1 min/day
~0.1 hrs/week
Adherence Friction
2/10
Effortless (Habitual)
Accessibility
over the counter
Granular Clinical Study Ledger

DunedinPACE Epigenetic Clock Speedometer Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
2
Human RCTs
2
Pooled N
1,257
Avg RoB
1.1 / 5
Human Clinical (n=1,037)Prospective CohortGRADE: Very High
Risk of Bias: 1

DunedinPACE, a DNA methylation biomarker of the pace of aging

Belsky DW, Caspi A, Corcoran DL, Sugden K, Poulton R, Moffitt TE, et al.•eLife•2022•N = 1,037•2600 wks
Intervention Protocol: Serial multi-system physiological biomarker tracking across 5 decades with Illumina DNA methylation array
Cohort: Longitudinal population-representative birth cohort tracked for 5 decades
Quantitative Endpoints & Effect Sizes
All-Cause Mortality Hazard per 1 SD Increase in DunedinPACE+64%
Hazard Ratio 1.64 (95% CI 1.45-1.85) for incident mortality and chronic diseasep < 0.0001
Pace of Biological vs Chronological Aging Precision+98%
Superior test-retest reliability (ICC = 0.96) compared to first- and second-generation clocksp < 0.0001
Clinical Takeaway:Validates DunedinPACE as the gold-standard third-generation epigenetic clock: measures the real-time speed of multi-organ aging per calendar year with unprecedented test-retest reliability (ICC 0.96) and precise mortality discrimination.
Public NIH / Health Agency Grant
PubMed: 35029144DOI
Human Clinical (n=220)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.1

Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults: CALERIE trial analysis

Waziry R, Ryan CP, Corcoran DL, Huffman KM, Kobor MS, Kothari M, Graf GH, Kraus VB, Belsky DW.•Nature Aging•2023•N = 220•104 wks
Intervention Protocol: 25% caloric restriction (CALERIE phase 2 RCT) over 2 years in non-obese healthy adults
Quantitative Endpoints & Effect Sizes
Slowing in Biological Pace of Aging (DunedinPACE)-3%
2-3% slowdown in DunedinPACE corresponding to a 10-15% reduction in long-term mortality riskp = 0.004
Clinical Takeaway:The first randomized controlled trial in healthy human adults demonstrating that lifestyle intervention (caloric restriction) significantly slows the DunedinPACE biological pace of aging, validating the biomarker as an actionable longevity intervention readout.
Public NIH / Health Agency Grant
PubMed: 36759714DOI
Chronological Evolution of Evidence

DunedinPACE Epigenetic Clock Speedometer Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

DunedinPACE Epigenetic Clock Speedometer Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

  • •Active hematologic malignancy or bone marrow transplantation (distorts blood DNA methylation signature)
  • •Severe acute systemic sepsis or recent blood transfusion within 48 hours

Pharmacological & Supplement Interactions

No high-risk pharmacokinetic interactions documented.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • •Minor discomfort, bruising, or transient bleeding at fingerstick or venipuncture site
Speculative / Theoretical Long-Term Concerns:
  • •Psychological distress or health anxiety if pace of aging score is higher than expected

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Extreme pediatric populations under 18 years old
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1.25x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)